Pneumococcal Vaccine Market Analysis

The market is segmented by vaccine, by age group, by end user and by region, out of which, the vaccine segment is bifurcated into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The segment for pneumococcal conjugate vaccine is anticipated to hold the largest share in the pneumococcal vaccine market on account of growing infant care awareness. Pneumococcal conjugate vaccine can be used against 13 types of pneumococcal bacteria. These vaccine are administered to infants at regular intervals till one year of age. The demand for pneumococcal vaccine is predicted to increase on account of growing pediatric population across the globe. The pneumococcal polysaccharide vaccine is anticipated to grow on the back of increasing administration among population above the age of 65.

Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others. The hospitals segment is estimated to hold the largest share in the market which can be attributed to growing healthcare infrastructure with rising number of hospitals which is anticipated to increase the demand for preventive vaccine around the world. On the other hand, the clinical segment is anticipated to grow at the highest rate over the forecast period as a result of increasing number of specialized and disease-specific clinics which is estimated to contribute to internal competition for better service and thereby raise the demand for pneumococcal vaccine. 

Our in-depth analysis of the global market includes the following segments